Both these treatments were often complicated by anemia because of the well-known dose-dependent intravascular hemolysis induced by RBV (and, to a lesser extent, also by IFN itself, which may contribute by suppressing the production of erythroid progenitor cells in the bone marrow) [24,25,26,27,28,29,30,31]. The gene discussed is IFNA1; the disease is hemolysis.